title: Update on the use of cinacalcet in the management of primary hyperparathyroidism.
abstract: Cinacalcet is an allosteric modulator of the calcium sensing receptor acting to sensitize this receptor to the extracellular calcium. Cinacalcet has been shown to be effective in reducing or normalizing serum calcium levels in several groups of patients with primary hyperparathyroidism (PHPT), including patients with mild to moderate PHPT, intractable PHPT, and parathyroid carcinoma, and in PHPT as a part of multiple endocrine neoplasia type 1. Cinacalcet slightly reduces PTH levels and has no effects on bone mineral density. Cinacalcet at low doses is well tolerated, but side effects are more frequent and severe when relatively high doses are needed to control hypercalcemia. Cinacalcet may be of benefit in a wide spectrum of PHPT severity, offering a novel therapeutic option for the control of hypercalcemia in PHPT patients who are not able to undergo parathyroidectomy. To what extent the reduction of serum calcium particularly in patients with mild to moderate hypercalcemia, translates into a clinical benefit is currently unknown. Moreover, there are no data as to whether long-term treatment with cinacalcet can prevent the complications of PHPT. Finally, more data are needed on the long-term safety of cinacalcet, particularly at the renal level.
authors: Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy. claudio.marcocci@med.unipi.it
authors: C
authors: C
authors: Marcocci
authors: F
authors: F
authors: Cetani
mesh_terms: D000069449:Cinacalcet; D019468:Disease Management; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000188:drug therapy*; D009281:Naphthalenes / Q000627:therapeutic use*
chemical_list: D009281:Naphthalenes; D000069449:Cinacalcet